Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting | Business Wire
Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib) | PharmaShots
Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer
Puma Biotechnology
Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of Neratinib in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS | Business Wire
Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta Win
Puma Biotechnology
Puma Hobbling Along a Year After Neratinib's Launch – B4 U Consent
Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer – pharmaceutical daily
hernix hashtag on Twitter
Buy Nerlynx (neratinib) • Price & Costs | TheSocialMedwork
Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive (NASDAQ:PBYI) | Seeking Alpha
Pint-Pharma - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America
PUMA BIOTECHNOLOGY, INC.
Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer - ChemDiv
Cancer hopeful neratinib plagued by diarrhea, analysis shows, but Puma cites a solution | FiercePharma
Buy Nerlynx (neratinib) • Price & Costs | TheSocialMedwork
Neratinib - Wikipedia
Puma Biotechnology: Neratinib Is Being Misunderstood (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China | Business Wire
A New Drug on the Horizon for HER2 Breast Cancer Patients | Avise Analytics
Buy Nerlynx (neratinib) • Price & Costs | TheSocialMedwork
Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | Business Wire
Puma Biotechnology, Inc. - Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer
Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT Trial)
